title: NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
authors: National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, UK. Electronic address: caroline.hall@nice.org.uk.
authors: Caroline J
authors: CJ
authors: Hall
authors: National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, UK.
authors: Nwamaka
authors: N
authors: Umeweni
authors: National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, UK.
authors: Helen
authors: H
authors: Knight
authors: National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, UK.
authors: Lindsay
authors: L
authors: Smith
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000556:secondary; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D006113:United Kingdom; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000096662:Ramucirumab